ArticleInternational journal of molecular sciences2026
Last Licensed Non-Classical Peptide Presenter HLA-F: Its Occurrence, Immunoediting Significance, and Possible Therapeutic Implications in Renal Cell Carcinoma.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Among non-classical human leukocyte antigen (HLA) molecules, HLA-F remains the most enigmatic. Its precise functions, including the recently described peptide-presenting capability, are still not fully understood. Renal cell carcinoma (RCC) is characterized by its resistance to radiotherapy and chemotherapy, and it is known for its immunogenicity. The prognostic significance of HLA-F expression in neoplastic cells has not been well defined. We evaluated HLA-F-specific mRNA transcripts in 73 RCC samples and 54 adjacent normal kidney parenchyma samples and statistically correlated the results with several clinicopathological parameters. Our analysis revealed that HLA-F is upregulated in RCC. Interestingly, higher HLA-F expression was associated with prolonged disease-free survival, more favorable pT stage, and lower WHO/ISUP grade. Given the potential for interferon-mediated aberrant activation of non-classical HLA molecules, assessment of HLA-F status could help identify RCC patients who might benefit from tailored neoadjuvant biological or immunological therapies. Overall, HLA-F may serve as a valuable prognostic biomarker in RCC, and further studies are warranted to elucidate its functional and clinical significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.